Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections

Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat infections caused from these organisms has fallen short of the emergent need. Specifically, resistance among Staphylococcus aureus and Enterococcus...

Descripción completa

Detalles Bibliográficos
Autores principales: Brade, Karrine D., Rybak, Jeffrey M., Rybak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811835/
https://www.ncbi.nlm.nih.gov/pubmed/26831328
http://dx.doi.org/10.1007/s40121-016-0103-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811835/
https://www.ncbi.nlm.nih.gov/pubmed/26831328
http://dx.doi.org/10.1007/s40121-016-0103-4

Ejemplares similares